Designer Babies: The Reality And Myths Of Genetic Optimization In Embryos

In June 2025, a Silicon Valley genomics company called Nucleus Genomics launched a product called Nucleus Embryo — a $5,999 software platform promising to help parents select IVF embryos optimised for intelligence, longevity, disease resistance, eye colour, BMI, and even left-handedness. This Designer Babies announcement was met with a mixture of fascination, alarm, and scepticism from scientists and ethicists around the world.

The fascination is understandable. The idea of choosing a child’s traits has captivated the human imagination for generations — from Plato’s Republic to Aldous Huxley’s Brave New World to the film GATTACA. The alarm is warranted. The history of eugenics — the attempt to improve human populations through selective reproduction — is one of the darkest chapters in modern history. And the scepticism is correct: the science behind Nucleus Embryo’s claims falls considerably short of what its marketing suggests.

This article separates the reality from the hype. It explains what genetic optimisation of embryos can and cannot actually do, why the most ambitious claims made by companies like Nucleus Genomics are not supported by current science, what legitimate preimplantation genetic testing does achieve, and why the ethical questions raised by this field matter regardless of where the science currently stands.

Table of Contents

What Preimplantation Genetic Testing Actually Does

The technology at the core of embryo genetic screening is called preimplantation genetic testing, or PGT. It is a well-established part of IVF practice, used for decades to screen embryos for chromosomal abnormalities and specific genetic mutations before implantation.

PGT works by taking a small biopsy of cells from an embryo at the blastocyst stage — typically five to six days after fertilisation, when the embryo consists of around 100 to 200 cells — and sequencing or testing the DNA. The results can be used to select embryos that do not carry specific genetic mutations, increasing the probability of a healthy pregnancy.

In its most established form — preimplantation genetic testing for monogenic conditions (PGT-M) — this technology is genuinely powerful and medically valuable. It can identify embryos carrying mutations for conditions caused by single genes with clear, predictable effects: cystic fibrosis, sickle cell disease, Huntington’s disease, BRCA1 and BRCA2 mutations associated with hereditary breast and ovarian cancer, and hundreds of other single-gene disorders. For families with a known inherited condition, PGT-M offers the ability to have a biological child free from that specific disease — a profound and legitimate medical benefit.

Preimplantation genetic testing for aneuploidies (PGT-A) screens embryos for chromosomal abnormalities — the wrong number of chromosomes — which are a major cause of failed implantation, miscarriage, and conditions like Down syndrome. Its clinical value is established, though debates continue about the best protocols for its use.

What these technologies cannot do — and what the science does not support — is reliably predict or select for complex traits like intelligence, personality, athleticism, or most measures of health that depend on interactions between hundreds or thousands of genes and the environment.

The Problem with Polygenic Scores

Nucleus Embryo and similar services base their complex trait predictions on polygenic scores — statistical summaries of the combined effect of thousands of genetic variants, each with a tiny individual effect, on a given trait. Polygenic scores for intelligence, height, BMI, and various disease risks have been developed from large genome-wide association studies, and they do have genuine predictive value at the population level. Across a large group of people, a higher polygenic score for educational attainment is statistically associated with more years of education.

The problem is that the predictive power of polygenic scores at the individual level — and particularly at the embryo selection level — is far weaker than this population-level validity might suggest. Several specific limitations make their use for embryo selection scientifically problematic.

First, the effect sizes involved are tiny. The polygenic score for intelligence explains perhaps ten to fifteen percent of the variance in IQ scores in the populations where it was developed. Selecting the highest-scoring embryo from a typical IVF cohort of five to ten embryos would be expected to produce an average advantage of only a few IQ points — an effect that is real but modest, and one that would be swamped by environmental factors including nutrition, education, parenting, and chance.

Second, polygenic scores developed in one population often perform poorly in others. Most large genome-wide association studies have been conducted predominantly in people of European ancestry. Scores derived from these studies are less accurate when applied to people of African, Asian, or other ancestries — creating a significant equity problem and limiting the applicability of the technology to diverse populations.

Third, complex traits are genuinely complex. Intelligence, for example, is not simply determined by additive effects of thousands of independent genetic variants. It involves gene-gene interactions, gene-environment interactions, developmental contingencies, and epigenetic effects that current polygenic scores cannot capture. The score is a statistical approximation of a biological reality that is considerably more complex than the model assumes.

Fourth — and perhaps most importantly — the use of polygenic scores for embryo selection involves a logical step that goes beyond what the underlying science validates. A polygenic score predicts average outcomes in populations. It does not reliably predict individual outcomes. The embryo with the highest polygenic score for intelligence is not guaranteed to become the most intelligent child. It is the embryo that, on average across a large population of similar embryos, would be expected to have a slightly higher IQ — a prediction that carries enormous uncertainty when applied to any single individual.

The Nucleus Embryo Claims: A Specific Assessment

Nucleus Embryo claimed to offer selection for resistance to heart disease, cancer, and other conditions; for intelligence and longevity; for body mass index; for eye colour and hair colour; and for characteristics like left-handedness and alcoholism predisposition. Each of these claims deserves specific scrutiny.

Disease resistance for cardiovascular disease and cancer is the most scientifically defensible claim in principle — polygenic scores for these conditions exist and have some predictive validity — but the effect sizes at the embryo selection scale are modest, and the reduction in lifetime risk achievable through embryo selection is likely smaller than the risk reduction achievable through lifestyle factors accessible to any child after birth.

Intelligence selection faces all of the limitations described above, amplified by the modest effect sizes and the enormous environmental determinants of cognitive development. The expected gain from selecting the highest-scoring embryo in a typical IVF cohort is a few points of IQ — meaningful at the population level, essentially invisible in an individual life.

Longevity selection has essentially no scientific basis at the embryo selection scale. Longevity is one of the most complex multifactorial traits in biology, with genetic factors accounting for perhaps 25% of the variance — and that 25% involving thousands of variants with tiny individual effects that interact with decades of environmental exposure in ways that cannot be modelled from embryo DNA.

Eye colour and hair colour are the most genetically tractable traits on the list — these are genuinely influenced by small numbers of genetic variants with relatively large effects. But selecting embryos for cosmetic traits raises obvious ethical concerns that have prompted regulatory responses in several countries. The UK explicitly prohibits the use of PGT for selecting embryos on the basis of sex or non-medical characteristics.

Left-handedness and alcoholism predisposition represent the weakest scientific claims. Handedness has a genetic component, but the specific variants involved are not well characterised and their predictive value is limited. Alcoholism risk is influenced by both genetic and environmental factors in proportions that vary enormously by individual context. Selecting against “alcoholism predisposition” at the embryo level is, at the current state of the science, largely theatre.

The Theranos Parallel and the Problem of Genomics Hype

Several prominent bioethicists and geneticists have drawn a comparison between Nucleus Embryo and Theranos — the blood testing company that claimed its technology could perform hundreds of diagnostic tests from a single drop of blood, attracted enormous investment, and was ultimately found to have vastly overstated its capabilities.

The parallel is imperfect — Nucleus Genomics is using real genomic technology, not fabricating data — but the structural similarity is real. A company makes dramatic claims about what its technology can do, markets it directly to consumers willing to pay a significant fee for the promise of control over something deeply important to them, and benefits from the fact that the technology is genuinely complex enough that most customers cannot independently evaluate the claims.

The difference in this case is that the customers are prospective parents making decisions about their children, and the claims concern human traits that carry enormous social weight — intelligence, health, longevity. The potential for harm from misleading claims in this context is significant: parents may pay for a service that provides less benefit than promised, may select embryos based on predictions that do not materialise, and may come to regard a child through a genetic lens that distorts the parent-child relationship in ways that are difficult to predict or reverse.

What the Ethical Debate Is Really About

The ethical concerns surrounding embryo genetic optimisation are not primarily about the specific capabilities of Nucleus Embryo. They are about the direction of travel — the gradual normalisation of selecting children on the basis of predicted traits — and the societal consequences that might follow.

The history of eugenics is the most important context here. In the early twentieth century, the scientific and political establishment in multiple countries embraced programmes of selective reproduction aimed at improving human populations — programmes that led to forced sterilisation, institutionalisation, and ultimately, in Nazi Germany, to systematic murder. The scientific premises of these programmes were false and the ethical premises were monstrous. But they were pursued by people who believed they were doing good, using the best science available to them at the time.

Contemporary genomic selection is different in crucial ways — it operates on embryos rather than born individuals, it is voluntary rather than coercive, and its scientific premises are more sophisticated. But the underlying logic — that some genetic profiles are more desirable than others, and that technology should be used to select for them — shares enough with historical eugenics to warrant serious caution.

Access and equity are equally significant concerns. If embryo selection technologies become effective and widely used, they will initially be available only to affluent families who can afford IVF and the additional cost of genetic screening. Over time, a society in which advantaged families can select embryos for health and cognitive traits while disadvantaged families cannot would see genetic inequality compound economic inequality in ways that could become self-reinforcing across generations.

For a look at the genetic technologies that are genuinely transforming medicine — and the careful regulatory frameworks being developed around them — see our articles on gene editing in 2026 and mitochondrial donation. And for an exploration of how the environment shapes gene expression in ways that no embryo selection technology can control, see our article on epigenetics.

Frequently Asked Questions

Can you really select a baby’s intelligence through IVF?

Not reliably. Polygenic scores for intelligence exist but explain only a fraction of the variance in cognitive outcomes, and their predictive power at the individual embryo level is very limited. Selecting the highest-scoring embryo from a typical IVF cohort would be expected to produce an average IQ advantage of only a few points — an effect easily outweighed by environmental factors like nutrition, education, and parenting.

What is preimplantation genetic testing?

Preimplantation genetic testing (PGT) is a technique used in IVF to screen embryos for genetic conditions before implantation. It is well-established and medically valuable for preventing single-gene disorders like cystic fibrosis, Huntington’s disease, and hereditary cancer syndromes. Its use for selecting complex traits like intelligence or longevity is scientifically controversial and not supported by current evidence.

What is a polygenic score?

A polygenic score is a statistical summary of the combined effect of thousands of genetic variants — each with a tiny individual influence — on a given trait. Polygenic scores have real predictive value at the population level but limited predictive power for any single individual, making their use for embryo selection scientifically problematic.

Is genetic optimisation of embryos legal?

This varies by country. In the UK, preimplantation genetic testing is permitted for preventing serious genetic diseases but is prohibited for selecting non-medical traits including sex and cosmetic characteristics. In the United States, regulation is less comprehensive and direct-to-consumer genomic services operate in a less restrictive environment. Most other countries restrict PGT to medical indications.

What is the difference between PGT and designer babies?

PGT for medical purposes — preventing inherited diseases — is a well-established and widely accepted medical technology. “Designer babies” refers to the selection or modification of embryos for non-medical traits like appearance, intelligence, or personality. The scientific basis for trait selection is weak, the ethical concerns are significant, and regulatory frameworks in most countries prohibit or restrict non-medical embryo selection.

Are companies like Nucleus Genomics regulated?

In the United States, direct-to-consumer genomic services are subject to limited oversight, particularly when they present their products as software rather than medical devices. Critics including bioethicists and geneticists have called for stronger regulation of companies making health claims based on polygenic scores applied to embryo selection. Regulatory frameworks in Europe and the UK are more restrictive.

Sources

About the Author

Baryon is the founder and editor of Web News For Us. Driven by a deep fascination with the biggest unanswered questions in science — from quantum physics and cosmology to the nature of consciousness and the genetic code written into every living cell — he has spent years studying modern physics, biology, and the history of scientific thought. He covers Science & AI, Space, Genetics & Research, and the timeless wisdom of history’s greatest thinkers and mystics.

If you have ever looked at the night sky and felt that pull to understand what is out there — or the wonder of an entire universe coiled inside your genes — you are in the right place.

Share on Facebook

Post on X

Save

Discover more from Web News For Us

Subscribe to get the latest posts sent to your email.